Clinical efficacy and safety analysis of brivudine in treatment of 9 cases of special herpes zoster
Objective To analyze the etiology,clinical characteristics,diagnosis,treatment and prognosis of 9 cases of special herpes zoster patients.Analyze the clinical efficacy and safety of brivudine in the treatment of elderly,liver and kidney dysfunction,immune dysfunction(or deficiency),and critically ill patients with herpes zoster,in order to im-prove clinical experience in the diagnosis and treatment of this disease,promote patient recovery,improve prognosis,and enhance quality of life.Methods Totally 9 cases of special herpes zoster patients admitted to the Dermatology De-partment of Henan Provincial People's Hospital between September 2021 and September 2022 were treated with brivudine orally at a dose of 125mg per day for a course of 7-10 days.Observe the clinical efficacy of patients,the numerical pain rating scale(NPRS)before and after treatment,and the occurrence of adverse reactions.Results All these 9 pa-tients with special herpes zoster were treated with brivudine and no new blisters appeared 1-2 days after treatment.The blister dries up for 2-5 days,and after 4-8 days,the blister scabs.The pain relief time was 1-2 days,and the com-plete disappearance time of the pain was 10-21 days.From 10-21 days,all herpes zoster patients have basically re-covered,and no patient has developed postherpetic neuralgia(PHN).Conclusion Brivudine can be used for the treat-ment of elderly patients,those with liver and kidney dysfunction,immune dysfunction(or defects),and severe herpes zoster.It can play an important role in relieving symptoms,accelerating rash healing,shortening the course of the disease,and blocking virus spread.It significantly improves clinical treatment effectiveness,reduces patient body pain,and does not increase adverse reactions.Brivudine is safe and worthy of clinical promotion and application.
BrivudineLiver and kidney dysfunctionImmune dysfunctionSevere herpes zoster
NETL
NSTL
万方数据
